Market Trends of Global Exocrine Pancreatic Insufficiency (EPI) Industry
This section covers the major market trends shaping the Exocrine Pancreatic Insufficiency Market according to our research experts:
Pancreatic Enzyme Replacement Therapy (PERT) Segment is Expected to Witness Growth Over the Forecast Period
Pancreatic enzyme replacement therapy (PERT) is the first-line therapy for patients with exocrine pancreatic insufficiency and is expected to hold the largest market share in the therapies segment. PERT is safe and effective in the treatment of pancreatic exocrine insufficiency. PERT includes various classes of drugs that are currently in use, including Pancrease, Creon, Pertzye, Viokace, and Zenpep. Since 2010, the Food and Drug Administration has approved various pancreatic enzyme replacement products for the treatment of exocrine pancreatic insufficiency. Therefore the majority of drugs comprise porcine pancreas extracts (pancrelipase). All but one of these preparations have a delayed release (Creon, Pancreaze, Zenpep, Pertzie), majorly due to enteric beads that protect the lipase from denaturation by stomach acid.
According to the study titled, 'Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma' in September 2021, Pancreatic enzyme replacement therapy (PERT) is associated with significantly prolonged survival and amelioration of maldigestion-related symptoms in patients with advanced pancreatic ductal adenocarcinoma (PDAC). In addition, since optimal PERT therapy is based on its clinical efficacy, the initial dose may be doubled or tripled based on clinical need and results. Indeed, PERT has demonstrated acceptable safety and tolerability over time, with reported side effects being abdominal pain, abdominal distension, and diarrhea.
Since pancreatic enzyme replacement therapy (PERT) therapy is safe and effective, as well as standard care for people with exocrine pancreatic insufficiency, therefore, considerable segment growth is anticipated over the forecast period.
North America is Expected to Dominate the Exocrine Pancreatic Insufficiency (EPI) Market
North America is expected to account for a significant share of the global exocrine pancreatic insufficiency (EPI) market due to the rise in the geriatric population and increasing prevalence and incidence of infectious diseases in the region. According to the study titled "Pancreatic Insufficiency," published in May 2022, excess alcohol is a well-known cause of chronic pancreatitis. Therefore, heavy drinkers have three times the risk of developing chronic pancreatitis, and the risk is further expected to increase among drinkers who are heavy smokers as well. Therefore, the high adoption of a sedentary lifestyle in this region is one of the major reasons for the high prevalence of chronic pancreatitis. For instance, according to the report published by the National Center for Drug Abuse Statistics in 2021, approximately 60.0% of Americans increased their alcohol consumption during the COVID-19 lockdown.
Key product launches, high concentration of market players or manufacturer's presence, acquisition and & partnerships among major players, and high prevalence of chronic pancreatitis in the United States are some of the factors driving the growth of the exocrine pancreatic insufficiency (EPI) market in the country. For instance, as per the study titled "Pancreatic Insufficiency," published in May 2022, chronic pancreatitis occurs in about 42 to 73 per 100,000 population in the United States and is the most common pancreatic disorder associated with pancreatic insufficiency, compared to 36 to 125 per 100,000 population in Japan, China, and India.
Therefore, owing to the aforesaid factors, considerable growth of the studied market is anticipated in the North America Region.
